usp7 activity hbx 41108 Search Results


usp7 inhibitor hbx 41108  (MedChemExpress)
93
MedChemExpress usp7 inhibitor hbx 41108
Usp7 Inhibitor Hbx 41108, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/usp7+activity+hbx+41108/HBX+41108/pmc12465477-57-10-17
Average 93 stars, based on 1 article reviews
usp7 inhibitor hbx 41108 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
small molecules that can inhibit ubp8 (usp8)  (Hybrigenics sa)
90
Hybrigenics sa small molecules that can inhibit ubp8 (usp8)
Small Molecules That Can Inhibit Ubp8 (Usp8), supplied by Hybrigenics sa, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/usp7+activity+hbx+41108/small+molecules+that+can+inhibit+ubp8++usp8+/10__1186_slash_1471___2091___9___s1___s7-205-23-0
Average 90 stars, based on 1 article reviews
small molecules that can inhibit ubp8 (usp8) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
usp7 activity hbx 41108  (Tocris)
90
Tocris usp7 activity hbx 41108
(A) Representative western blot analysis showing TCF7L2 protein levels after treatment with cycloheximide (CHX) (30 μg/ml) at different time points (0, 3, 6, 9, 12 h) in C3H/10T1/2 cells. Ponceau was used as the loading control. (B) Quantification of three independent experiments showing TCF7L2 protein levels (as a percentage [%]) after CHX treatment. (C) Representative western blot analysis showing TCF7L2 protein levels after treatment with CHX at different time points (0, 3, 6, 9 h) in wild-type muscle PDGFRα + FAPs. (D) (A) BioGRID interactome analysis of the human TCF7L2 protein. Black circles mark the protein-protein interaction between TCF7L2 and RNF4, RNF43, RNF138, NLK, UHRF2, UBE2I, UBE2L6, USP4, UBR5, and XIAP. (E) In silico prediction of TCF7L2 ubiquitination sites, showing the aminoacidic sequence of human TCF7L2 protein variant 1. Potential TCF7L2-ubiquitinated lysine residues were ranked and are shown in red . http://www.ubpred.org ; http://bdmpub.biocuckoo.org/ (F) Representative western blot analysis showing TCF7L2 and CCN2/CTGF protein levels after TGF-β1 (1 ng/ml) and MG132 (15 μM) treatments (9 h). Tubulin was used as the loading control. (G) Quantification of TCF7L2 protein levels. *** P <0.001; ** P <0.005; * P <0.05 by one-way ANOVA with Dunnett’s post-test; n =6. (H) Representative western blot analysis from three independent experiments that evaluate total levels of TCF7L2 following <t>USP7</t> small-molecule inhibitor HBX 41108 (10 μM) and CHX treatments at different time points (0, 4, 6, 8 h) in C3H/10T1/2 MSCs. Tubulin was used as the loading control.
Usp7 Activity Hbx 41108, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/usp7+activity+hbx+41108/HBX+41108/bio_rxiv__2020__01__05__895334-263-80-88
Average 90 stars, based on 1 article reviews
usp7 activity hbx 41108 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
small molecules that can inhibit ubp7 (usp7) hbx 41108  (Hybrigenics sa)
90
Hybrigenics sa small molecules that can inhibit ubp7 (usp7) hbx 41108
(A) Representative western blot analysis showing TCF7L2 protein levels after treatment with cycloheximide (CHX) (30 μg/ml) at different time points (0, 3, 6, 9, 12 h) in C3H/10T1/2 cells. Ponceau was used as the loading control. (B) Quantification of three independent experiments showing TCF7L2 protein levels (as a percentage [%]) after CHX treatment. (C) Representative western blot analysis showing TCF7L2 protein levels after treatment with CHX at different time points (0, 3, 6, 9 h) in wild-type muscle PDGFRα + FAPs. (D) (A) BioGRID interactome analysis of the human TCF7L2 protein. Black circles mark the protein-protein interaction between TCF7L2 and RNF4, RNF43, RNF138, NLK, UHRF2, UBE2I, UBE2L6, USP4, UBR5, and XIAP. (E) In silico prediction of TCF7L2 ubiquitination sites, showing the aminoacidic sequence of human TCF7L2 protein variant 1. Potential TCF7L2-ubiquitinated lysine residues were ranked and are shown in red . http://www.ubpred.org ; http://bdmpub.biocuckoo.org/ (F) Representative western blot analysis showing TCF7L2 and CCN2/CTGF protein levels after TGF-β1 (1 ng/ml) and MG132 (15 μM) treatments (9 h). Tubulin was used as the loading control. (G) Quantification of TCF7L2 protein levels. *** P <0.001; ** P <0.005; * P <0.05 by one-way ANOVA with Dunnett’s post-test; n =6. (H) Representative western blot analysis from three independent experiments that evaluate total levels of TCF7L2 following <t>USP7</t> small-molecule inhibitor HBX 41108 (10 μM) and CHX treatments at different time points (0, 4, 6, 8 h) in C3H/10T1/2 MSCs. Tubulin was used as the loading control.
Small Molecules That Can Inhibit Ubp7 (Usp7) Hbx 41108, supplied by Hybrigenics sa, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/usp7+activity+hbx+41108/usp7+inhibitors/pmc02582801-192-12-0
Average 90 stars, based on 1 article reviews
small molecules that can inhibit ubp7 (usp7) hbx 41108 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
inhibitors of usp7 p5091  (Progenra Inc)
90
Progenra Inc inhibitors of usp7 p5091
(A) Representative western blot analysis showing TCF7L2 protein levels after treatment with cycloheximide (CHX) (30 μg/ml) at different time points (0, 3, 6, 9, 12 h) in C3H/10T1/2 cells. Ponceau was used as the loading control. (B) Quantification of three independent experiments showing TCF7L2 protein levels (as a percentage [%]) after CHX treatment. (C) Representative western blot analysis showing TCF7L2 protein levels after treatment with CHX at different time points (0, 3, 6, 9 h) in wild-type muscle PDGFRα + FAPs. (D) (A) BioGRID interactome analysis of the human TCF7L2 protein. Black circles mark the protein-protein interaction between TCF7L2 and RNF4, RNF43, RNF138, NLK, UHRF2, UBE2I, UBE2L6, USP4, UBR5, and XIAP. (E) In silico prediction of TCF7L2 ubiquitination sites, showing the aminoacidic sequence of human TCF7L2 protein variant 1. Potential TCF7L2-ubiquitinated lysine residues were ranked and are shown in red . http://www.ubpred.org ; http://bdmpub.biocuckoo.org/ (F) Representative western blot analysis showing TCF7L2 and CCN2/CTGF protein levels after TGF-β1 (1 ng/ml) and MG132 (15 μM) treatments (9 h). Tubulin was used as the loading control. (G) Quantification of TCF7L2 protein levels. *** P <0.001; ** P <0.005; * P <0.05 by one-way ANOVA with Dunnett’s post-test; n =6. (H) Representative western blot analysis from three independent experiments that evaluate total levels of TCF7L2 following <t>USP7</t> small-molecule inhibitor HBX 41108 (10 μM) and CHX treatments at different time points (0, 4, 6, 8 h) in C3H/10T1/2 MSCs. Tubulin was used as the loading control.
Inhibitors Of Usp7 P5091, supplied by Progenra Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/usp7+activity+hbx+41108/usp7+inhibitors/pm21111230-109-10-3
Average 90 stars, based on 1 article reviews
inhibitors of usp7 p5091 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


(A) Representative western blot analysis showing TCF7L2 protein levels after treatment with cycloheximide (CHX) (30 μg/ml) at different time points (0, 3, 6, 9, 12 h) in C3H/10T1/2 cells. Ponceau was used as the loading control. (B) Quantification of three independent experiments showing TCF7L2 protein levels (as a percentage [%]) after CHX treatment. (C) Representative western blot analysis showing TCF7L2 protein levels after treatment with CHX at different time points (0, 3, 6, 9 h) in wild-type muscle PDGFRα + FAPs. (D) (A) BioGRID interactome analysis of the human TCF7L2 protein. Black circles mark the protein-protein interaction between TCF7L2 and RNF4, RNF43, RNF138, NLK, UHRF2, UBE2I, UBE2L6, USP4, UBR5, and XIAP. (E) In silico prediction of TCF7L2 ubiquitination sites, showing the aminoacidic sequence of human TCF7L2 protein variant 1. Potential TCF7L2-ubiquitinated lysine residues were ranked and are shown in red . http://www.ubpred.org ; http://bdmpub.biocuckoo.org/ (F) Representative western blot analysis showing TCF7L2 and CCN2/CTGF protein levels after TGF-β1 (1 ng/ml) and MG132 (15 μM) treatments (9 h). Tubulin was used as the loading control. (G) Quantification of TCF7L2 protein levels. *** P <0.001; ** P <0.005; * P <0.05 by one-way ANOVA with Dunnett’s post-test; n =6. (H) Representative western blot analysis from three independent experiments that evaluate total levels of TCF7L2 following USP7 small-molecule inhibitor HBX 41108 (10 μM) and CHX treatments at different time points (0, 4, 6, 8 h) in C3H/10T1/2 MSCs. Tubulin was used as the loading control.

Journal: bioRxiv

Article Title: TGF-β-driven downregulation of the Wnt/β-Catenin transcription factor TCF7L2/TCF4 in PDGFRα + fibroblasts

doi: 10.1101/2020.01.05.895334

Figure Lengend Snippet: (A) Representative western blot analysis showing TCF7L2 protein levels after treatment with cycloheximide (CHX) (30 μg/ml) at different time points (0, 3, 6, 9, 12 h) in C3H/10T1/2 cells. Ponceau was used as the loading control. (B) Quantification of three independent experiments showing TCF7L2 protein levels (as a percentage [%]) after CHX treatment. (C) Representative western blot analysis showing TCF7L2 protein levels after treatment with CHX at different time points (0, 3, 6, 9 h) in wild-type muscle PDGFRα + FAPs. (D) (A) BioGRID interactome analysis of the human TCF7L2 protein. Black circles mark the protein-protein interaction between TCF7L2 and RNF4, RNF43, RNF138, NLK, UHRF2, UBE2I, UBE2L6, USP4, UBR5, and XIAP. (E) In silico prediction of TCF7L2 ubiquitination sites, showing the aminoacidic sequence of human TCF7L2 protein variant 1. Potential TCF7L2-ubiquitinated lysine residues were ranked and are shown in red . http://www.ubpred.org ; http://bdmpub.biocuckoo.org/ (F) Representative western blot analysis showing TCF7L2 and CCN2/CTGF protein levels after TGF-β1 (1 ng/ml) and MG132 (15 μM) treatments (9 h). Tubulin was used as the loading control. (G) Quantification of TCF7L2 protein levels. *** P <0.001; ** P <0.005; * P <0.05 by one-way ANOVA with Dunnett’s post-test; n =6. (H) Representative western blot analysis from three independent experiments that evaluate total levels of TCF7L2 following USP7 small-molecule inhibitor HBX 41108 (10 μM) and CHX treatments at different time points (0, 4, 6, 8 h) in C3H/10T1/2 MSCs. Tubulin was used as the loading control.

Article Snippet: The TGFBR1 inhibitor SB525334 (used at 5 μM; S8822, Sigma-Aldrich), p38 MAPK SB203580 inhibitor (used at 20 μM; 5633, Cell Signaling Technology), PI3K/AKT inhibitor LY294002 (used at 10 μM; 440202, Merck-Calbiochem), the inhibitor of MEK1/2/ERK1/2 kinases UO126 (used at 10 μM; 9903, Cell Signaling Technology), Smad3 inhibitor SIS3 (used at 6 μM; 1009104-85-1, Merck-Calbiochem), the inhibitor of JNK activity SB600125 (used at 20 μM; Cell Signaling Technology), trichostatin A (TSA) (used at 10 μM; T8552, Sigma-Aldrich), and the inhibitor of USP7 activity HBX 41108 (used at 10uM; 4285; Tocris) were all diluted in DMSO.

Techniques: Western Blot, Control, In Silico, Ubiquitin Proteomics, Sequencing, Variant Assay